The debt repurchase reduces leverage and interest burden, a credit-positive signal for the convertible noteholders and common equity. Monitor for any subsequent equity issuance or cash burn updates in the next 10-Q. The averaging period based on common stock trading price introduces some uncertainty on final cost.
OMER drugs
OMER drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $10.28entry
- T+1 · 5mo ago +0.49%α +0.80% · $10.33
- T+5 · 5mo ago +4.28%α +5.95% · $10.72
- T+20 · 4mo ago −10.31%α −10.84% · $9.22
- T+60 · 2mo ago +69.84%α +67.95% · $17.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omeros Corporation repurchased up to $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 for a total purchase price of up to approximately $34.0 million (including accrued interest and other obligations). The repurchase reduces outstanding convertible debt from ~$70.8 million to ~$54.8 million, lowering leverage and interest expense. The transaction is credit-positive for the preferred/convertible noteholders, reducing debt overhang and improving the equity cushion.
Key Facts
- Omeros agreed to repurchase up to $16.0 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029
- Total purchase price up to approximately $34.0 million, including accrued and unpaid interest
- Repurchases expected to close between July 6, 2026 and July 16, 2026
- Approximately $54.8 million aggregate principal amount of Notes will remain outstanding after the repurchase
- Repurchase reduces outstanding debt from ~$70.8 million to ~$54.8 million
Financial Impact
Debt reduction of ~$16M principal (22.6% of outstanding notes) at a premium of ~$18M over par, funded by the company
Risk Factors
- The repurchase premium ($34M for $16M principal) is significant, indicating the notes were trading well above par
- Remaining $54.8M in notes still outstanding; future conversion/dilution risk persists
- Cash used for repurchase reduces liquidity for operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021040 |
| Document: 0001437749-26-021040-index-headers.html | 0001437749-26-021040 |
| Document: 0001437749-26-021040-index.html | 0001437749-26-021040 |
| Document: 0001437749-26-021040.txt | 0001437749-26-021040 |
Track record
12 reports on OMER
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
- Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
- Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
- Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
- Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
- Jul 6, 202619w ago 8-K Neutral 4/10 Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
- Jun 18, 202621w ago 8-K Bullish 5/10 Viewing Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers